TH9619
Advanced refractory solid tumors (Colorectal Cancer, NSCLC, HNSCC, Gastric/GEJ Cancer)
Key Facts
About One-carbon Therapeutics
One-carbon Therapeutics is a Swedish, clinical-stage biotech founded in 2020, focused on developing novel small-molecule cancer therapies. The company's core innovation is targeting the one-carbon metabolism pathway, specifically the overexpressed enzymes MTHFD1 and MTHFD2, to induce cancer cell death via thymidine depletion and disruption of DNA repair. With its lead candidate TH9619 in a Phase 1/2 trial (ODIN study) for advanced solid tumors and a recent SEK 153 million financing, the company is positioned to advance a potentially first-in-class precision oncology asset. Its strategic collaboration with Tempus aims to bolster biomarker and patient stratification strategies.
View full company profile